EPI 589

Drug Profile

EPI 589

Alternative Names: (R)-troloxamide quinone; EPI-589

Latest Information Update: 26 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Edison Pharmaceuticals
  • Developer BioElectron Technology; Sumitomo Dainippon Pharma
  • Class Alkadienes; Antidementias; Antiparkinsonians; Benzoquinones; Cyclohexenes; Small molecules
  • Mechanism of Action Antioxidants; NAD(P)H dehydrogenase (quinone) modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

  • 25 Sep 2018 Efficacy and adverse events data from the phase IIa Amyotrophic lateral sclerosis (ALS) trial released by BioElectron
  • 05 Sep 2018 EPI 589 is still in phase II trials for Amyotrophic lateral sclerosis and Parkinson's disease in USA
  • 01 Aug 2018 Edison Pharmaceuticals is now called BioElectron Technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top